Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Johnson and Johnson

- PMLiVE

Johnson & Johnson’s multiple myeloma treatment approved by US FDA

The approval was based on phase 3 data showing survival rates of 83.3% after three years

- PMLiVE

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

In 2022, nearly one million new patients were diagnosed with gastric cancer

- PMLiVE

Sanofi’s multiple myeloma treatment Sarclisa accepted for FDA priority review

The second most common haematologic malignancy is responsible for more than 180,000 new global diagnoses every year

- PMLiVE

J&J applies for EU authorisation for one-dose COVID-19 vaccine

Submission is based on top-line efficacy and safety data from the phase 3 ENSEMBLE trial

- PMLiVE

Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Final analysis demonstrates a 35% reduction in the risk of death in mHSPC patients

- PMLiVE

J&J’s one-dose COVID-19 vaccine proves 66% effective in phase 3 trial

Vaccine was 57% effective against South African strain

- PMLiVE

J&J could launch its single-dose COVID-19 vaccine in March

Chief scientific officer Paul Stoffels said J&J is aiming for one billion doses in 2021

- PMLiVE

J&J advances COVID-19 vaccine into second phase 3 trial

ENSEMBLE study will enrol 60,000 people worldwide

- PMLiVE

J&J inks $1bn deal with US for coronavirus vaccine

Agreement includes manufacturing and delivery of 100 million doses

- PMLiVE

J&J’s COVID-19 vaccine generates positive pre-clinical results

Experimental vaccine begins first-in-human trial this month

- PMLiVE

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

Potential treatment for patient group with no FDA-approved drugs

- PMLiVE

Geron poleaxed as partner J&J abandons only pipeline drug

Shares drop by two-thirds as questions raised on imetelstat’s potential

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links